About Videregen
Videregen is a Healthcare company based in Liverpool (United Kingdom) founded in 2012. Tissue repair is advanced through thymus stem cell science by Videregen. It operates on a HealthTech model. Videregen has raised $2.59 million across 4 funding rounds from investors including European Union, Spark Impact and London Business Angels. The company has 8 employees. Videregen offers products and services including BioThymus Technology. Its focus areas include Biotechnology and Stem Cell Therapy.
Company details
Thymus stem cell science is translated into treatments by Videregen, targeting diseases related to thymus dysfunction, ageing, T cell development, and autoimmunity. The proprietary BioThymus technology platform is utilized to replicate native thymus biology, enabling rejuvenation of thymus function and education of T cells. Potential applications in treating athymia, reducing autoimmunity, and creating transplant tolerance are explored. Additionally, age-related immune deterioration is addressed through targeted thymus rejuvenation, aiming to halt or reverse associated pathologies. The focus is placed on innovative solutions within the biotechnology sector.
- Headquarters Liverpool, United Kingdom
- Employees 8
- SectorsHealthcare
- Email••••••••
- Website videregen.com
- Social LinkedIn
- Legal Name Videregen
- Total Equity Funding$2.59M (USD)
in 4 rounds
- Latest Funding Round$1.19M (USD), Grant
Jan 2016
- InvestorsEuropean Union
& 2 more
- Employee Count8
Products & Services of Videregen
Videregen offers a comprehensive portfolio of products and services, including BioThymus Technology.
Thymus function is rejuvenated through advanced stem cell technology.
Funding Insights of Videregen
Videregen has successfully raised a total of $2.59M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $1.19 million completed in January 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.59M
- Total Rounds 4
- Last Round Grant — $1.19M
- First Round $1.97M
(Sep 2014)
- Investors Count 3
All 4 funding rounds of Videregen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2016 | $1.19M | Grant | – | – | |
| Dec 2015 | $7.44M | Grant | – | – | – |
| Jul 2015 | $623,292 | Seed | – | – | |
| Sep 2014 | $1.97M | Seed | – | – |
3 investors in total: 3 institutional.
Investors in Videregen
Videregen has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Spark Impact and London Business Angels.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt is extended to UK life sciences companies. | 2011 | sparkimpact.co.uk | Chester, United Kingdom | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Delivers comprehensive investment services for businesses. | 1982 | lbangels.co.uk | London, United Kingdom |
Investor details for Videregen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Videregen
3 people are tracked at Videregen (1 in leadership, 2 in board & advisors); the tracked headcount is 8.
| Name | Role | Group |
|---|---|---|
Doug Quinn | CFO | Leadership |
Martin Hunt | Chairman | Board & advisors |
Cathy Prescott | Non-Executive Director | Board & advisors |
Complete people profiles for Videregen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Videregen
3 dated milestones of Videregen across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Videregen is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Grant, of $1.2M.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Videregen (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Videregen
Videregen was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Videregen is headquartered in Liverpool, United Kingdom.
Videregen is a funded company, having raised a total of $2.59M across 4 funding rounds to date. The company's 1st funding round was a Seed of $1.97M, raised on Sep 2014.
Videregen has 8 employees.
Thymus stem cell science is translated into treatments by Videregen, targeting diseases related to thymus dysfunction, ageing, T cell development, and autoimmunity. The proprietary BioThymus technology platform is utilized to replicate native thymus biology, enabling rejuvenation of thymus function and education of T cells. Potential applications in treating athymia, reducing autoimmunity, and creating transplant tolerance are explored. Additionally, age-related immune deterioration is addressed through targeted thymus rejuvenation, aiming to halt or reverse associated pathologies. The focus is placed on innovative solutions within the biotechnology sector.
Videregen offers BioThymus Technology.
Videregen has 3 investors. Key investors include European Union, Spark Impact, and London Business Angels.
Videregen operates through Videregen.